Liquidia Beheer

Beheer criteriumcontroles 3/4

De CEO Liquidia is Roger Jeffs, benoemd in Jan2022, heeft een ambtstermijn van 2.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.89M, bestaande uit 14.1% salaris en 85.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.39% van de aandelen van het bedrijf, ter waarde $ 21.45M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 5.1 jaar.

Belangrijke informatie

Roger Jeffs

Algemeen directeur

US$4.9m

Totale compensatie

Percentage CEO-salaris	14.1%
Dienstverband CEO	2.8yrs
Eigendom CEO	2.4%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

Is Liquidia (NASDAQ:LQDA) A Risky Investment?

Jul 18

Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher

Jan 19

Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable

Dec 20

Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Aug 17

Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues

Mar 18

Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Feb 06

Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 25

Analyse CEO-vergoeding

Hoe is Roger Jeffs's beloning veranderd ten opzichte van Liquidia's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$112m
Mar 31 2024	n/a	n/a	-US$108m
Dec 31 2023	US$5m	US$689k	-US$79m
Sep 30 2023	n/a	n/a	-US$58m
Jun 30 2023	n/a	n/a	-US$51m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$11m	US$325k	-US$41m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$41m
Dec 31 2021	US$93k	n/a	-US$35m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$89k	n/a	-US$60m

Compensatie versus markt: De totale vergoeding ($USD 4.89M ) Roger } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.18M ).

Compensatie versus inkomsten: De vergoeding van Roger is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Roger Jeffs (62 yo)

2.8yrs

Tenure

US$4,889,498

Compensatie

Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and serves as its Chief Executive Officer from January 3, 2022. He...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Roger Jeffs	CEO & Director	2.8yrs	US$4.89m	2.39% $ 21.5m
Michael Kaseta	COO & CFO	4yrs	US$2.43m	0.12% $ 1.0m
Russell Schundler	General Counsel & Corporate Secretary	3.7yrs	US$2.06m	0.39% $ 3.5m
William Kenan	Co-Founder	20.8yrs	geen gegevens	geen gegevens
Ginger Denison	Co-Founder	20.8yrs	geen gegevens	geen gegevens
Sarah Krepp	Vice President of People & Culture	1.4yrs	geen gegevens	geen gegevens
Jason Adair	Chief Business Officer	1.3yrs	geen gegevens	0.073% $ 652.7k
Scott Moomaw	Chief Commercial Officer	4yrs	geen gegevens	0.067% $ 598.0k
Rajeev Saggar	Chief Medical Officer	2.3yrs	geen gegevens	0.099% $ 892.7k
Michael Hunter	Senior Vice President of Manufacturing Operations	less than a year	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LQDA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Roger Jeffs	CEO & Director	4yrs	US$4.89m	2.39% $ 21.5m
Arthur Kirsch	Independent Director	8.2yrs	US$186.91k	0.038% $ 340.4k
Joanna Horobin	Independent Director	5.2yrs	US$176.91k	0% $ 0
Burton Goldstein	Board Observer	no data	geen gegevens	geen gegevens
Michael Raab	Board Observer	no data	geen gegevens	geen gegevens
Martin Lagod	Board Observer	no data	geen gegevens	geen gegevens
Stephen Bloch	Independent Chairman	15.3yrs	US$211.91k	0% $ 0
Paul Manning	Independent Director	4.8yrs	US$170.66k	7.28% $ 65.4m
David Johnson	Independent Director	3.6yrs	US$174.41k	0% $ 0
Damian deGoa	Director	3.9yrs	US$166.91k	0.057% $ 507.7k
Ramandeep Singh	Independent Director	6.8yrs	US$178.16k	0% $ 0
Katherine Rielly-Gauvin	Independent Director	5.1yrs	US$175.66k	0% $ 0

5.1yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LQDA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Liquidia Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Liquidia Corporation, Annual General Meeting, Jun 20, 2024

CEO & Director recently sold US$452k worth of stock

Liquidia Corporation Announces Updates to Operations Leadership

Insufficient new directors

Independent Director recently bought US$2.0m worth of stock

Recent updates

Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024

Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024

Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million.

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million.

Liquidia Corporation Files Litigation to Challenge Regulatory Exclusivity Blocking Access to Yutrepia (Treprostinil) Inhalation Powder for Patients Suffering with PAH and PH-ILD

Consensus revenue estimates decrease by 49%, EPS upgraded

No longer forecast to breakeven

New minor risk - Share price stability

Price target decreased by 7.1% to US$25.71

Liquidia Corporation Announces U.S. Food and Drug Administration Grants Tentative Approval of YUTPIA®? (Treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Consensus revenue estimates fall by 45%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Liquidia Corporation to Report Q2, 2024 Results on Aug 07, 2024

Is Liquidia (NASDAQ:LQDA) A Risky Investment?

Price target increased by 10% to US$27.67

No longer forecast to breakeven

District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch

Consensus revenue estimates increase by 18%, EPS downgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

No longer forecast to breakeven

Liquidia Corporation to Report Q1, 2024 Results on May 14, 2024

Liquidia Corporation, Annual General Meeting, Jun 20, 2024

Liquidia Corporation Provides Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA Approval of YUTREPIA™ (treprostinil) Inhalation Powder

CEO & Director recently sold US$452k worth of stock

Consensus EPS estimates fall by 15%, revenue upgraded

Price target increased by 29% to US$27.33

Full year 2023 earnings: EPS and revenues miss analyst expectations

Liquidia Corporation to Report Fiscal Year 2023 Results on Mar 13, 2024

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder

Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder

Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher

Liquidia Corporation Announces Updates to Operations Leadership

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Liquidia Corporation Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP

Insufficient new directors

Forecast to breakeven in 2026

Price target increased by 31% to US$18.29

Independent Director recently bought US$2.0m worth of stock

Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $24.999999 million.

New minor risk - Shareholder dilution

Liquidia Corporation has filed a Follow-on Equity Offering in the amount of $24.999999 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Liquidia Corporation to Report Q3, 2023 Results on Nov 07, 2023

FDA Accepts Liquidia Corporation's Submission to Add PH-ILD to YUTREPIA™ Label

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?

Consensus EPS estimates fall by 34%, revenue upgraded

New minor risk - Profitability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Liquidia Corporation to Report Q2, 2023 Results on Aug 10, 2023

Liquidia Corporation Submits Amendment to Add Ph-Ild Indication to Tentatively Approved Nda for Yutpia (Treprostinil) Inhalation Powder

Liquidia Corporation Announces U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Price target increased by 15% to US$16.17

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.30 loss in 1Q 2022)

Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues

No longer forecast to breakeven

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?

Forecast to breakeven in 2025

Price target increased to US$14.83

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Liquidia Corporation to Report Q3, 2022 Results on Nov 08, 2022